Hepcidins

• 

  Subject Areas on Research

  • ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. 
  • Age-dependent retinal iron accumulation and degeneration in hepcidin knockout mice. 
  • An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. 
  • Anemia of inflammation: the cytokine-hepcidin link. 
  • Anemia of inflammation: the hepcidin link. 
  • Biomarkers of erythropoiesis response to intravenous iron in a crossover pilot study in unexplained anemia of the elderly. 
  • Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. 
  • Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. 
  • Closing the iron gate. 
  • Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. 
  • Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice. 
  • Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. 
  • Evidence of relative iron deficiency in platelet- and plasma-pheresis donors correlates with donation frequency. 
  • Forging a field: the golden age of iron biology. 
  • Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice. 
  • Hepcidin and disordered mineral metabolism in chronic kidney disease. 
  • Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. 
  • Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. 
  • Hepcidin expression in human airway epithelial cells is regulated by interferon-γ. 
  • Hepcidin induction by transgenic overexpression of Hfe does not require the Hfe cytoplasmic tail, but does require hemojuvelin. 
  • Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice. 
  • Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. 
  • Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. 
  • Interleukin-6 induces hepcidin expression through STAT3. 
  • Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. 
  • Iron homeostasis and erythropoiesis. 
  • Iron homeostasis and inherited iron overload disorders: an overview. 
  • Iron overload in hereditary tyrosinemia type 1 induces liver injury through the Sp1/Tfr2/hepcidin axis. 
  • Late stage erythroid precursor production is impaired in mice with chronic inflammation. 
  • Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. 
  • Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. 
  • Pathophysiologic mechanisms of anemia of chronic disease. 
  • Proinflammatory state, hepcidin, and anemia in older persons. 
  • Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. 
  • Skeletal muscle hemojuvelin is dispensable for systemic iron homeostasis. 
  • The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation. 
  • The ins and outs of iron homeostasis. 
  • The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. 
  • The role of hepatocyte hemojuvelin in the regulation of bone morphogenic protein-6 and hepcidin expression in vivo. 
  • The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. 
  • Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. 
  • Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice.